Raloxifene preserves bone strength and bone mass in ovariectomized rats

Endocrinology

Volumn 135, Issue 5, 1994, Pages 2001-2005

  Turner, C H ^a   Sato, M ^b   Bryant, H U ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; CYCLODEXTRIN DERIVATIVE; DRUG VEHICLE; ETHINYLESTRADIOL; KETAMINE; RALOXIFENE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FEMUR NECK; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; UTERUS WEIGHT;

ANIMAL; BIOMECHANICS; BONE AND BONES; BONE DENSITY; COMPARATIVE STUDY; DENSITOMETRY; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FEMUR NECK; LUMBAR VERTEBRAE; ORGAN WEIGHT; OVARIECTOMY; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; UTERUS;

EID: 0028061884     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/endo.135.5.7956922     Document Type: Article

References (35)

1. Gallagher JC, Goldgar D, Moy A 1987 Total bone calcium in normal women: effect of age and menopause status. J Bone Miner Res 2:491-496
2. Gotfredsen A, Hadberg A, Nilas L, Christiansen C 1987 Total body bone mineral in healthy adults. J Lab Clin Med 110:362-368
3. Nordin BEC, Need AG, Chatterton BE, Horowitz M, Morris HA 1990 The relative contributions of age and years since menopause to postmenopausal bone loss. J Clin Endocrinol Metab 70:83-88
4. Riggs BL, Melton III LJ 1986 Involutional osteoporosis. N Engl J Med 314:1676-1686
5. Lindsay R, Hart DM, Forrest C, Baird C 1980 Prevention of spinal osteoporosis in oophorectomised women. Lancet 1151-1154
6. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR 1980 Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198
7. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Vaz AAL, Lyritis GP, Mazzuoli G, Mira vet L, Passeri M, Cano RP, Rapado A, Ribot C 1992 Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:1124-1128
8. Ziel HK, Finkle WD 1975 Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167-1170
9. Smith DC, Prentice R, Thompson DJ, Herrmann WL 1975 Association of exogenous estrogen and endometrial carcinoma. N Engl Med 293:1164-1167
10. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL 1991 A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990
11. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C 1989 The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293-297
12. Brinton LA, Schairer C 1993 Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 15:66-79
13. Dupont WD, Page DL 1991 Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67-72
14. Chakraborty PK, Brown JL, Ruff CB, Nelson MF, Mitchell AS 1991 Effects of long-term treatment with estradiol or clomiphene citrate on bone maintenance, and pituitary and uterine weights in ovariectomized rats. J Steroid Biochem Mol Biol 40:725-729
15. Moon LY, Wakley GK, Turner RT 1991 Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. Endocrinology 129:1568-1574
16. Turner RT, Wakley GK, Hannon KS, Bell NH 1988 Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122:1146-1150
17. Jordan VC, Phelps E, Lindgren JU 1987 Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35
18. Sato M, McClintock G, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW 1994 Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 9:715-724
19. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
20. Black LJ, Jones CD, Facone JR 1983 Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sei 32:1031-1036
21. Pak CYC, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S, Adams-Huet B, Reisch JS 1994 Slow-release sodium fluoride in the management of postmenopausal osteoporosis. Ann Intern Med 120:625-632
22. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton III LJ 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809
23. Beary DF 1969 The effects of fluoride and low calcium on the physical properties of the rat femur. Anat Rec 164:305-316
24. Turner CH, Akhter MP, Heaney RP 1992 The effects of fluoridated water on bone strength. J Orthop Res 10:581-587
25. Wronski TJ, Cintron M, Doherty AL, Dann LM 1988 Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123:681-686
26. Wronski TJ, Dann LM, Scott KS, Cintron M 1989 Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360-366
27. Kalu DN 1991 The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192
28. Jones CD, Suarez T, Massey EH, Black LJ, Tinsley FC 1979 Synthesis and anti-estrogenic activity of [3, 4-dihydro-2-(4-methox-yphenyl)-l-napthalenyl] [4-(2-pyrrolidinyl) ethoxy]-phenyl] meth-anone, methanesulfonic acid salt. J Med Chem 22:962-966
29. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608
30. Keller TS, Spengler DM, Carter DR 1986 Geometric, elastic and structural properties of maturing rat femora. J Orthop Res 4:57-67
31. Evans G, Bryant H, Sato M, Turner RT 1993 Raloxifene is a tissue specific estrogen agonist. J Bone Miner Res 8:S134 (Abstract)
32. Turner RT, Colvard DS, Speisberg TC 1990 Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology 127:1346-1351
33. Turner CH, Dunipace AJ, Wilson M, Sun TC 1993 Fluoride intake severely reduces bone strength in older rats. J Bone Miner Res 8 (Suppl 1):S238 (Abstract)
34. Meissner WA, Sommers SC, Sherman G 1957 Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer 10:500-509
35. Draper MW, Flowers DE, Huster WJ, Neild JA, Effects of raloxifene (LY139481 HC1) on biochemical markers of bone, lipid metabolism in healthy postmenopausal women. Proceedings of the Fourth International Symposium on Osteoporosis, Hong Kong, 1993, pp 119-121 (Abstract)